INSTITUTIONAL AND PRIVATE FUNDING

Clonal Heterogeneity in Cancer: Liquid Biopsy as High Performance Technology

Funding agency	VLC-BioClinic	Amount	6.000€
PI	Andrés Cervantes (INCLIVA) -Rosa Noguera (UV)
Duration	1 year
Abstract	Collaboration between the translational research groups in neuroblastoma (NB, DP-UV) and colorectal cancer (CCR, INCLIVA) is proposed to achieve a more effective development of the liquid biopsy in cancer by combining and transferring two innovative techniques in the diagnosis, Prognosis and prediction in cancer. Currently cancer screening involves both the analysis of tissue samples and biological fluids, as well as sophisticated imaging techniques. The project aims to generate a model to increase the sensitivity of the liquid biopsy in cancer and to be able to catalog and integrate all the genomic findings obtained by implementing the microscopic digital imaging and genomic DNA scanning (ctDNA) Dissociated in NB and CCR respectively. The NB microscopic digital imaging analysis model, used in> 500 biopsies, will be extrapolated to the specific characteristics of CCR biopsies. It will be necessary to adapt the measurement tools and methods of quantification and analysis of the tumor cell, stromal and the amount of elements of the extracellular matrix. As a result of the adaptation of the model will obtain the key morphological information to be able to validate the findings observed at the subclonal level in the biopsy and in the blood of the patients. On the other hand, the reference parameters of the isolation, quantification and genomic analysis of ctDNA used in serum samples from patients affected by RCC will be adjusted to achieve the identification of subclonal alterations in serum of children affected by NB. Genetic alterations have recently been described that define molecular groups of patients, susceptible to targeted pharmacological therapies. As a result of the study, it is planned to identify the subclones of altered genes present in the tumor samples thus contributing to increase the clinical potentiality of the liquid biopsy. The information obtained by these two pathways, together with the information (morphological and genetic) previously obtained from tumor biopsies, will be the basis for the optimization and the complex detection of clonal and subclonal heterogeneity with respect to alterations in genes Tumor suppressors and oncogenes.

Analysis of microRNA expression in tumor tissue of young women under 35 years

Funding agency	Fundación Le Cadó – contra el cáncer de mama	Amount	45.000€
PI	Gloria Ribas / Ana Lluch
Duration	01/01/2011-31/12/2013
Abstract

Validation of microRNAs by quantitative RT-PCR probes

Funding agency	INCLIVA	Amount	6.800€
PI	Gloria Ribas
Duration	30/01/2013 – 29/01/2015
Abstract

Development of personalized antitumor therapies of cancer patients with somatic mutations of PTPN11

Funding agency	INCLIVA	Amount	2.000€
PI	Andrés Cervantes
Duration	01/01/2014 – 31/12/2014
Abstract

Hyperacetylation of nuclear heterogeneous riboproteins (hnRNPs) as a final pathway of anti-EGFR drug resistance in prostate cancer

Funding agency	AECC	Amount	135.000€
PI	Ana Isabel Gil Tébar
Duration	09/2014 – 10/2018
Abstract

Application of magnetic resonance diffusion and perfusion in preoperative staging of rectal cancer: Detection of metastatic lymph nodes and evaluation of the response to neoadjuvant chemotherapy

Funding agency	Fundación ERESA	Amount	30.000€
PI	Andrés Cervantes
Duration	01/01/2012-31/12/2012
Abstract

Mechanisms of resistance to EGFR inhibitors. Epigenomic and protein acetylation study in KRAS mutated and wild cell lines and their evaluation in patients with colon cancer

Funding agency	Fundació Gent x Gent	Amount	23.000€
PI	Andrés Cervantes
Duration	2009 – 2012
Abstract

Phenotypic and genotypic characterization of cutaneous melanoma patients in the Spanish population

Funding agency	Fundación Mutua Madrileña de Automovilismo	Amount	40.000€
PI	Gloria Ribas
Duration	01/06/2007-31/12/2009
Abstract